The Board of MacroGenics, Inc. approved an increase in board size from ten to eleven members and appointed Dr. Emil Kuriakose as a Class II Director and Dr. Michael Vasconcelles as a Class III Director, effective October 30, 2026. Both directors are independent and will serve until their respective successors are elected at the 2027 and 2028 annual meetings. Each received an initial option to purchase 44,000 shares and a restricted stock unit grant for 7,500 shares under the company's equity incentive plan. MacroGenics is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for cancer treatment.
